Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | RORC | P51449 | 13/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6366962 | 0.84 | STAT3 (0.41) | CA12CA1CA9ALDH1A1RORC | |
| SCHEMBL509795 | 0.81 | CA12 (0.52) | CA12CA1CA9ALDH1A1RORC | |
| SCHEMBL3375330 | 0.80 | CYP17A1 (0.53) | CA12CA1CYP17A1 | |
| SCHEMBL15316351 | 0.79 | CA12 (0.50) | CA12CA1CA9ALDH1A1RORC | |
| SCHEMBL1025076 | 0.79 | SIRT2 (0.48) | CA12CA1RORCCYP17A1KAT6A | |
| SCHEMBL30000904 | 0.77 | ATR (0.44) | CA12CA1CA9ALDH1A1CYP17A1 | |
| SCHEMBL31263553 | 0.76 | CA12 (0.50) | CA12CA1CA9ALDH1A1RORC | |
| SCHEMBL13197992 | 0.76 | CA12 (0.58) | CA12CA1CA9ALDH1A1CYP17A1 | |
| SCHEMBL30031129 | 0.76 | CA12 (0.52) | CA12CA1CA9ALDH1A1RORC | |
| SCHEMBL2487493 | 0.75 | LMNA (0.46) | CA12CA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108383789-A | Pyrazole compound as CRTH2 antagonists | 艾克提麦斯医药品有限公司 | 2018-08-10 | — | — | CN | disclosed |
| EP-2528901-B9 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-25 | — | — | EP | disclosed |
| CN-102884051-B | Pyrazole compounds as CRTH2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-16 | — | — | CN | disclosed |
| CN-104829535-A | Pyrazole compounds as CRTH2 antagonists | BOEHRINGER INGELHEIM INT | 2015-08-12 | — | — | CN | disclosed |
| EP-2528901-B1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-8791272-B2 | Pyrazole compounds as CRTH2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| EP-2528901-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20120028938-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092140-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028938-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, HRH1, HRH3 | CA12 4515/4885CA1 4167/4885CA9 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.